bluuebunny/crossref_metadata_2025_split huggingface dataset:
A comprehensive in silico analysis of putative outer membrane and secretory hydrolases from the pathogenic Leptospira: Possible implications in pathogenesis
Authors: Shankar Umate Nachiket , Shiraz Mohd. , Kumar Pankaj , Akif Mohd. 
Published: May 2024

AbstractOuter surface/membrane and virulent secretory proteins are primarily crucial for pathogenesis. Secreted and outer membrane hydrolases of many pathogens play an important role in attenuating the host immune system. Leptospira expresses many such proteins, and few have been characterized to display various roles, including host immune evasion. However, identification, classification, characterization, and elucidation of the possible role of Leptospira’s outer membrane and secretory hydrolases have yet to be explored. In the present study, we used bioinformatics tools to predict exported proteins from the pathogenic Leptospira proteome. Moreover, we focused on secretory and outer membrane putative hydrolases from the exported proteins to generate a deeper understanding. Our analysis yielded four putative outer/secretory hydrolases, LIC_10995, LIC_11183, LIC_11463, and LIC_12988, containing α/β hydrolase fold and displayed similarity with lipase motif. Moreover, their conservation analysis of the predicted hydrolases across the spectrum of different Leptospira species showed high clustering with the pathogenic species. Outer membrane and secretory proteins with lipolytic activity may have a role in pathogenesis. This is the first bioinformatics analysis of secretory and outer membrane α/β hydrolases from leptospiral species. However, experimental studies are indeed required to unravel this possibility.
Self‐Supporting Solid Electrolyte Based on Supramolecular Interaction for Stable Li Metal Batteries
Authors: Guan Lixiang , Xiao Shijun , Bai Xiang , Zhang Jiahui , Su Jia , Lu Tiantian , Hou Lifeng , Du Huayun , Wei Huan , Liu Xiaoda , Yang Chengkai , Wie Yinghui , Wang Qian 
Published: May 2024

AbstractLi metal batteries based on solid polymer electrolytes offer the benefits of high energy density and safety, as well as extended cycling life, making them an excellent candidate for the next‐generation battery system. However, current solid polymer electrolytes still suffer from low ion conductivity and Li+ transfer number, which seriously restricts its practical application. Herein, a self‐supporting composite solid polymer electrolyte was prepared, where phenolic resin rich in hydroxyl groups (BR) and polyethylene oxide (PEO) are mixed evenly and poured onto a cellulose membrane in one step. In such an electrolyte, PEO and BR combine to form intermolecular hydrogen bonds, lowering the crystallinity of PEO and increasing the Li+ transfer number. Lastly, the obtained solid electrolytes exhibited a high ion conductivity (1.1×10−4 S cm−1) and Li+ transfer number (0.53), as well as improved electrochemical window. Consequently, Li || Li symmetrical cells can run stably for more than 700 h at 0.1 mA cm−2/0.25 mAh cm−2. And full cells with LiFePO4 cathode can also demonstrate high discharge capacity of 152.12 mAh g−1 and rate performance. We believe that such a design based on supramolecular interaction offer a new avenue to advanced solid polymer electrolytes.
Demystification of luminescence properties and the near imperceptible thermal quenching of Sm3+‐doped tungstate phosphors
Authors: R. Kiran , A. Princy , Kennedy Masilla S. Moses , Sayyed Mohammad I. , Mishra Vikash , Kamath Sudha D. 
Published: May 2024

AbstractUltra‐high thermally stable Ca2MgWO6:xSm3+ (x = 0.5, 0.75, 1, 1.25, and 1.5 mol%) double perovskite phosphors were synthesized through solid‐state reaction method. Product formation was confirmed by comparing the X‐ray diffraction (XRD) patterns of the phosphors with the standard reference file. The structural, morphological, thermal, and optical properties of the prepared phosphor were examined in detail using XRD, Fourier transform infrared spectra, scanning electron microscopy, diffused reflectance spectra, thermogravimetric analysis (TGA), photoluminescence emission, and temperature‐dependent PLE (TDPL). It was seen that the phosphor exhibited emission in the reddish region for the near‐ultraviolet excitation with moderate Colour Rendering Index values and high colour purity. The optimized phosphor (x = 1.25 mol%) was found to possess a direct optical band gap of 3.31 eV. TGA studies showed the astonishing thermal stability of the optimized phosphor. Additionally, near‐zero thermal quenching was seen in TDPL due to elevated phonon‐assisted radiative transition. Furthermore, the anti‐Stokes and Stokes emission peaks were found to be sensitive toward the temperature change and followed a Boltzmann‐type distribution. All these marked properties will make the prepared phosphors a suitable candidate for multifield applications and a fascinating material for further development.
Carbon‐based nanodots for biomedical applications and clinical transformation prospects
Authors: Ding Haizhen , Xiao Tenghui , Ren Fangfang , Qiu Yu , Shen Zhiyang , Chen Xuecheng , Mijowska Ewa , Chen Hongmin 
Published: May 2024

AbstractCarbon dots (CDs), emerging as a promising class of nanomaterials, have garnered significant interest in the field of biomedicine due to their unique physicochemical properties. This review provides a comprehensive overview of the recent advancements in the biomedical applications of CDs, emphasizing their potential for revolutionizing diagnostics, therapy, and bio‐imaging. We discuss the synthesis and functionalization of CDs, which are pivotal in tailoring their properties for specific biomedical applications. The applications of CDs in bioimaging include fluorescence imaging, magnetic resonance imaging, photoacoustic imaging, etc. Additionally, this review delves into the benefits of CDs in the treatment of diseases including cancer, inflammation and Alzheimer's, etc. Finally, we look forward to the future of CDs in the field of biomedicine, emphasizing the necessity of interdisciplinary collaboration to overcome current obstacles and facilitate the clinical translation of CDs‐based technologies. This review aims to provide a summary and perspectives on the latest developments of CDs in biomedicine, hoping to inspire further research in this rapidly advancing field.
Breaking piezoelectric limits of molecules for biodegradable implants
Authors: Hao Jianhua , Malek Nik Ahmad Nizam Nik , Kamaruddin Wan Hairul Anuar , Li Jianhua 
Published: May 2024

AbstractIn the quest for optimizing biodegradable implants, the exploration of piezoelectric materials stands at the forefront of biomedical engineering research. Traditional piezoelectric materials often suffer from limitations in biocompatibility and biodegradability, significantly impeding their in vivo study and further biomedical application. By leveraging molecular engineering and structural design, a recent innovative approach transcends the conventional piezoelectric limits of the molecules designed for biodegradable implants. The biodegradable molecular piezoelectric implants may open new avenues for their applications in bioenergy harvesting/sensing, implanted electronics, transient medical devices and tissue regeneration.
Trastuzumab deruxtecan in previously treated HER2‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France
Authors: Petit Thierry , Hajjaji Nawale , Antoine Eric‐Charles , Benderra Marc‐Antoine , Gozy Michel , Foa Cyril , Mouysset Jean‐Loup , Grenier Julien , Mousseau Mireille , Mailliez Audrey , Saghatchian Mahasti , Lachaier Emma , Desmoulins Isabelle , Hennequin Audrey , Maes Patricia , Loirat Delphine , Ricci Francesco , Diéras Véronique , Berton Dominique , Tiong Florence Lai , Teixeira Luis , Dohollou Nadine , Lévy Christelle , Bachelot Thomas , Pierga Jean‐Yves 
Published: May 2024

AbstractBackgroundEarly access program (formerly cohort Temporary Authorization for Use) was granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial which demonstrated its efficacy and safety in HER2‐positive metastatic/unresectable breast cancer after ≥2 anti‐HER2‐based regimens received at metastatic stage.MethodsThis multicenter real‐world early access program included HER2‐positive metastatic/unresectable breast patients pretreated with at least two lines of anti‐HER2 regimens who received T‐DXd 5.4 mg/kg intravenously in monotherapy every 3 weeks.ResultsFour hundred and fifty‐nine patients (median age, 58 years; hormone receptor‐positive, 67%; brain metastases, 28.1%) received T‐DXd. Before inclusion, 81.7% of patients had radiation therapy and 76.5% had undergone surgery. Median number of prior metastatic treatment lines was four (range, 2–22); 99.8% patients had received trastuzumab, 94.8% trastuzumab emtansine and 79.3% pertuzumab. Follow‐up was performed from September 30, 2020 to March 30, 2021; when the early access program stopped, the median duration of T‐DXd treatment was 3.4 (range, 0–7.8) months. In 160 patients with available tumor assessment, objective response rate was 56.7% and 12.1% had progression. In 57 patients with available brain tumor assessment, complete or partial intracranial response was reported for 35.7% patients and 5.4% had progression. A total of 17 (3.7%) patients with interstitial lung disease (ILD) was reported with no cases of ILD‐related death.ConclusionsIn this early access program in patients with heavily pretreated HER2‐positive metastatic/unresectable breast cancer, T‐DXd had antitumor activity with a similar response to that reported in previous clinical studies. T‐DXd was well tolerated and no new safety signals were observed.
Artificial neural network identified a 20‐gene panel in predicting immunotherapy response and survival benefits after anti‐PD1/PD‐L1 treatment in glioblastoma patients
Authors: Wang Yaning , Wang Zihao , Guo Xiaopeng , Cao Yaning , Xing Hao , Wang Yuekun , Xing Bing , Wang Yu , Yao Yong , Ma Wenbin 
Published: May 2024

AbstractBackgroundImmune checkpoint inhibitors (ICIs) are a promising immunotherapy approach, but glioblastoma clinical trials have not yielded satisfactory results.ObjectiveTo screen glioblastoma patients who may benefit from immunotherapy.MethodsEighty‐one patients receiving anti‐PD1/PD‐L1 treatment from a large‐scale clinical trial and 364 patients without immunotherapy from The Cancer Genome Atlas (TCGA) were included. Patients in the ICI‐treated cohort were divided into responders and nonresponders according to overall survival (OS), and the most critical responder‐relevant features were screened using random forest (RF). We constructed an artificial neural network (ANN) model and verified its predictive value with immunotherapy response and OS.ResultsWe defined two groups of ICI‐treated glioblastoma patients with large differences in survival benefits as nonresponders (OS ≤6 months, n = 18) and responders (OS ≥17 months, n = 8). No differentially mutated genes were observed between responders and nonresponders. We performed RF analysis to select the most critical responder‐relevant features and developed an ANN with 20 input variables, five hidden neurons and one output neuron. Receiver operating characteristic analysis and the DeLong test demonstrated that the ANN had the best performance in predicting responders, with an AUC of 0.97. Survival analysis indicated that ANN‐predicted responders had significantly better OS rates than nonresponders.ConclusionThe 20‐gene panel developed by the ANN could be a promising biomarker for predicting immunotherapy response and prognostic benefits in ICI‐treated GBM patients and may guide oncologists to accurately select potential responders for the preferential use of ICIs.
Long non‐coding RNA NEAT1 promotes aerobic glycolysis and progression of cervical cancer through WNT/β‐catenin/PDK1 axis
Authors: Su Min , Liang Ziyan , Shan Shidong , Gao Yang , He Li , Liu Xuelian , Wang Anjin , Wang Hua , Cai Hongbing 
Published: May 2024

AbstractBackgroundCervical cancer is one of the most common gynecological cancers. Accumulated evidence shows that long non‐coding RNAs (lncRNAs) play essential roles in cervical cancer occurrence and progression, but their specific functions and mechanisms remain to be further explored.MethodsThe RT‐qPCR assay was used to detect the expression of NEAT1 in cervical cancer tissues and cell lines. CCK‐8, colony formation, flow cytometry, western blotting, and Transwell assays were used to evaluate the impact of NEAT1 on the malignant behavior of cervical cancer cells. Glucose consumption, lactate production, ATP levels, ROS levels, MMP levels, and the mRNA expressions of glycolysis‐related genes and tricarboxylic acid cycle‐related genes were detected to analyze the effect of NEAT1 on metabolism reprograming in cervical cancer cells. The expressions of PDK1, β‐catenin and downstream molecules of the WNT/β‐catenin signaling pathway in cervical cancer cells and tissues were detected by western blotting, RT‐qPCR, immunofluorescence and immunohistochemistry assays.ResultsThis study investigated the role and possible molecular mechanism of lncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) in cervical cancer. Our results showed that NEAT1 was highly expressed in cervical cancer tissues and cell lines. Downregulation of NEAT1 inhibited the proliferation, migration, invasion and glycolysis of cervical cancer cells, while overexpression of NEAT1 led to the opposite effects. Mechanistically, NEAT1 upregulated pyruvate dehydrogenase kinase (PDK1) through the WNT/β‐catenin signaling pathway, which enhanced glycolysis and then facilitated cervical cancer metastasis. Furthermore, NEAT1 maintained the protein stability of β‐catenin but did not affect its mRNA level. We also excluded the direct binding of NEAT1 to the β‐catenin protein via RNA pull‐down assay. The suppressive impact of NEAT1 knockdown on cell proliferation, invasion, and migration was rescued by β‐catenin overexpression. The WNT inhibitor iCRT3 attenuated the carcinogenic effect induced by NEAT1 overexpression.ConclusionIn summary, these findings indicated that NEAT1 may contribute to the progression of cervical cancer by activating the WNT/β‐catenin/PDK1 signaling axis.
High incidence of lung cancer death after curative endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma
Authors: Tajiri Ayaka , Tsujii Yoshiki , Nishida Tsutomu , Inoue Takuya , Maekawa Akira , Kitamura Shinji , Yamaguchi Shinjiro , Nishihara Akihiro , Yamada Takuya , Ogiyama Hideharu , Murayama Yoko , Yamamoto Shunsuke , Egawa Satoshi , Uema Ryotaro , Yoshihara Takeo , Hayashi Yoshito , Takehara Tetsuo 
Published: May 2024

AbstractBackground and AimFollowing treatment of superficial esophageal squamous cell carcinoma (ESCC), surveillance for a second primary malignancy (SPM) is necessary. However, detailed evidence regarding the timing and prognosis of SPMs is insufficient. We aimed to clarify the details of SPMs and their effects on patient outcomes.MethodsThis retrospective, multicenter study involved 11 hospitals. Patients with superficial ESCC curatively resected using endoscopic submucosal dissection between May 2005 and December 2012, were included in this study.ResultsThe 5‐year survival rate of 187 patients was 92.6% during a median follow‐up duration of 96.8 months. Thirty‐one patients died, 14 of whom died of SPMs. Compared to patients with SPMs detectable by esophagogastroduodenoscopy (EGD), patients with SPMs detectable only by modalities other than EGD had a significantly higher mortality rate (p < 0.001). Patients with second primary lung cancer (LC) had a high mortality rate (56.3%). Univariate and multivariate analyses showed that multiple Lugol‐voiding lesions (LVLs) tended to be associated with SPMs (p = 0.077, hazard ratio [HR] 4.43, 95% confidence interval [CI]: 0.91–6.50), and metachronous ESCC was an independent risk factor for the incidence of second primary LC (p = 0.037, HR 3.51, 95% CI: 1.08–11.41).ConclusionsSPMs that cannot be detected by EGD, such as LC, must be considered after the curative resection of ESCC. We suggest strict screening by both EGD and computed tomography for patients with multiple LVLs or metachronous ESCC to detect SPMs in their early stages.
Impact of obesity on sentinel lymph node biopsy outcomes and survival in breast cancer patients: A single‐center retrospective study
Authors: Pang Jian , Li Lun , Yin Nana , Dai Mei , Zheng Shuyue , Chen Ming , Xue Jingyan , Wu Jiong 
Published: May 2024

AbstractBackgroundSentinel lymph node biopsy (SLNB) is a common choice for axillary surgery in patients with early‐stage breast cancer (BC) who have clinically negative lymph nodes. Most research indicates that obesity is a prognostic factor for BC patients, but studies assessing its association with the rate of positive sentinel lymph nodes (SLN) and the prognosis of patients with early BC undergoing SLNB are limited.MethodsBetween 2013 and 2016, 7062 early‐stage BC patients from the Shanghai Cancer Center of Fudan University were included. Based on the Chinese Body Mass Index (BMI) classification standards, the patients were divided into three groups as follows: normal weight, overweight, and obese. Propensity score matching analysis was used to balance the baseline characteristics of the participants. Logistic regression analysis was used to determine the association between obesity and positive SLN rate. Cox regression analysis was used to investigate whether obesity was an independent prognostic factor for early‐stage BC patients who had undergone SLNB.ResultsNo significant association was observed between obesity and positive SLN rate in early‐stage BC patients who had undergone SLNB. However, multivariate analysis revealed that compared to patients with normal BMI, the overall survival (hazard ratio (HR) 2.240, 95% confidence interval (CI) 1.27–3.95, p = 0.005) and disease‐free survival (HR 1.750, 95% CI 1.16–2.62, p = 0.007) were poorer in patients with high BMI.ConclusionObesity is an independent prognostic factor for early‐stage BC patients who undergo SLNB; however, it does not affect the positive SLN rate.
Potential efficacy of crizanlizumab in treating priapism in sickle cell disease: A case report
Authors: Abdulgayoom Mohammed , Afana Mohammad S. , Alshurafa Awni , Yassin Mohamed A. 
Published: May 2024

Key Clinical MessageThis report documents the treatment of a 41‐year‐old male with sickle cell disease (SCD) and repeated stuttering priapism using crizanlizumab, which alleviated the priapism but induced a significant vaso‐occlusive crisis during the second infusion. Encouragingly, no subsequent vaso‐occlusive crises occurred. However, the potential for infusion‐related adverse events warrants close supervision. Further research is necessary to explore its full benefits on priapism management.
Septic pulmonary embolism arising from a small temporal boil in a patient with diabetes mellitus type 2: A rare case report
Authors: Yildirim Sanem , Yigit Yavuz , Alkahlout Baha Hamdi , Mohamed Eslam Hussein , Azad Aftab Mohammad 
Published: May 2024

Key Clinical MessageSeptic pulmonary embolism (SPE) can originate from unusual sources like small boils, warranting consideration of diverse etiologies in respiratory distress. Prompt diagnosis, tailored antibiotics, and vigilant complication management optimize outcomes. Early recognition and treatment of minor infections, especially in diabetes are crucial.
Ischemic stroke as an initial presentation of neurosyphilis in a newly diagnosed HIV patient: A case report and literature review
Authors: Moursi Moaz O. , Hamam Wael , Hajjar Adnan , Es‐Salim Mohammad , Aboukhalaf Soha , Jamil Omar , Zahid Muhammad 
Published: May 2024

Key Clinical MessageWith syphilis resurgence, physicians should be more vigilant to infection‐induced cerebral vasculitis in high‐risk patients presenting with neurological symptoms. In this case, neurosyphilis should not be missed. Thorough serologic screening and lumbar puncture are crucial for diagnosis, and further research is needed for safe and effective treatments in these populations.
Luspatercept's use in a patient with transfusion‐dependent beta‐thalassemia and intrathoracic extramedullary hematopoiesis (EMH)
Authors: Seijari Mohammed Najdat , Alshurafa Awni , Yassin Mohamed A. 
Published: May 2024

Key Clinical MessageThis case report and literature review examine the use of a relatively novel agent in a transfusion‐dependent beta‐thalassemia patient with extramedullary hematopoiesis (EMH). It examines the benefits and risks associated with its use and reviews the available literature while highlighting the drug's results in our patient with a higher risk profile.AbstractBeta thalassemia can be complicated by EMH, which causes different symptoms based on location and size. Luspatercept is a new agent approved for transfusion‐dependent thalassemia and Non‐transfusion‐dependent thalassemia (NTDT). Still, its use in patients with EMH was not well studied, and literature showed an increased risk of EMH expansion or development of new masses after its use. We discuss, in this case, the results of luspatercept treatment in a patient with transfusion‐dependent thalassemia who is considered high risk for its use due to the patient's specific characteristics (history of symptomatic intrathoracic EMH, previous splenectomy, refusal to use antithrombotic medications). While also highlighting the benefits of using luspatercept regarding decreasing the iron overload and improving hemoglobin levels and examining how it was used safely to manage a transfusion‐dependent thalassemia patient with an extramedullary hematopoiesis mass with no adverse events of note.
Transverse colon volvulus: A case report of an uncommon cause of acute abdomen in pediatrics
Authors: Ortega Evenildo Martinez , Ruano Dollis De Jesús Rodríguez , Al‐Zoubi Raed M. , Alansari Amani N. 
Published: May 2024

Key Clinical MessageTransverse colonic volvulus (TCV) is a serious condition with a mortality rate of up to 33%. It is very rare, especially in children. Despite its rarity, surgeons should have a high index of suspicion and include it in the list of differential diagnoses, especially in patients with developmental delays and associated uncommon syndromes. Resection and anastomosis, whether as a one‐stage or two‐stage procedure, proved to be the best treatment options for children. Since prompt identification and management are vital, this paper presents useful information on the presentation, treatment, and outcome of this case report.
Steroid responsive encephalopathy associated with autoimmune thyroiditis (SREAT) presenting as subacute psychosis: Case report and literature review
Authors: Abdelmahmuod Elabbass A. , Jasim Noor , Ibrahim Buthaina , Mokhtar Marwa 
Published: May 2024

Key Clinical MessageClinicians should consider autoimmune thyroiditis in patients presenting with neuropsychiatric symptoms and promptly initiate appropriate investigations and treatment, such as corticosteroids, to improve clinical outcomes.